Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesNovel evidence-based systemic lupus erythematosus (sle) responder index described in peer reviewed publication as potentially significant advance in lupus drug development
Human Genome Sciences, 09/08/09
Human Genome Sciences, Inc. announced publication by the journal Arthritis Care & Research of an article describing the development and use of a novel evidence–based systemic lupus erythematosus Responder Index selected as the primary endpoint of two pivotal Phase 3 clinical trials of BENLYSTA™ (belimumab) in serologically active patients with SLE. This primary endpoint was accepted by the FDA under a Special Protocol Assessment agreement for the Phase 3 trials.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Telmisartan/amlodipine: approved for high blood pressure
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
A Clinical Review of Echinocandins in Pediatric Patients
Annals of Pharmacotherapy, 12/16/09
Sanofi Pasteur expands study of vaccine against Clostridium difficile into the U.S.
Sanofi-aventis, 12/16/09
Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor